Your session is about to expire
← Back to Search
Comprehensive Imaging for COVID-19 Recovery
N/A
Waitlist Available
Led By Joao Lima, MD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Age: 18+
Diagnosed with COVID-19 at any point starting March 2020
Timeline
Screening 3 weeks
Treatment Varies
Follow Up analyzed within 6 months of study completion
Awards & highlights
Study Summary
This trial will look at how severe COVID-19 infections affect major organs and systems to help prevent, detect, and manage complications. It will use imaging tech to compare patients to matched controls.
Who is the study for?
This trial is for adults over 18 who had COVID-19, split into those hospitalized and not hospitalized. It's not for patients still on ventilators, those over 300 lbs due to MRI limits, with certain heart conditions or severe kidney issues (GFR <45), pregnant women, people allergic to contrast agents used in scans, with internal electrical devices like pacemakers, or severe claustrophobia.Check my eligibility
What is being tested?
The study uses advanced imaging techniques - MRI and ultra-high resolution CT scans - to examine long-term organ damage in recovered COVID-19 patients. Participants will be compared with matched controls to understand the chronic effects of the virus on major organs.See study design
What are the potential side effects?
Potential side effects mainly relate to the use of contrast agents during imaging which can cause allergic reactions. The process may also be uncomfortable for individuals with claustrophobia due to enclosed spaces in MRI machines.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am 18 years old or older.
Select...
I was diagnosed with COVID-19 since March 2020.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ analyzed within 6 months of study completion
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~analyzed within 6 months of study completion
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Degree and extent of fibrosis
Secondary outcome measures
Assessment of Perfusion
Trial Design
2Treatment groups
Experimental Treatment
Group I: Non-HospitalizedExperimental Treatment2 Interventions
Participants who had COVID-19 but did not require hospitalization secondary to their illness.
Group II: HospitalizedExperimental Treatment2 Interventions
Participants who were hospitalized due to their COVID-19 illness.
Find a Location
Who is running the clinical trial?
Johns Hopkins UniversityLead Sponsor
2,259 Previous Clinical Trials
14,820,443 Total Patients Enrolled
34 Trials studying COVID-19
26,765 Patients Enrolled for COVID-19
Canon Medical Systems, USAIndustry Sponsor
9 Previous Clinical Trials
584 Total Patients Enrolled
Joao Lima, MDPrincipal InvestigatorJohns Hopkins School of Medicine
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You weigh more than 300 pounds, which is too heavy for the MRI table.I do not have any current severe illnesses.You have been admitted to the hospital because of a COVID-19 infection.I have an irregular heartbeat or a severe block in my heart's electrical signals.My kidney function, measured by GFR, is below 45 mL/min.You are allergic to gadolinium or iodine-based contrast agents.I have severe heart failure symptoms.I am 18 years old or older.I have severe claustrophobia.I am on a ventilator due to COVID-19.I was diagnosed with COVID-19 since March 2020.
Research Study Groups:
This trial has the following groups:- Group 1: Hospitalized
- Group 2: Non-Hospitalized
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are there any vacancies left for participation in this clinical inquiry?
"The clinicaltrial.gov website reports that this medical study is no longer actively recruiting patients, having first been posted on October 14th 2020 and last updated June 23rd 2023. Despite this fact, there are still 752 other trials enrolling participants at present time."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger